Welcome
Support Centre
11 October 2008 
ISRCTN Register - International Standard Randomized Controlled Trial Number
Trial registration
Unique identification scheme
International databases
home  |   my details  |   ISRCTN Register  |   mRCT  |   UKCTG  |   links  |   information  |   press
Find trials
ISRCTN Register
tips on searching

Registration
New application
Updating record

Information
introduction
governing board
ISRCTN FAQs
data set
letter of agreement
request information
guidance notes

[ Print-friendly version ]
Comparison of Second-Line Hormonal Agents Medroxyprogesterone Acetate and Aminoglutethimide in Advanced Breast Cancer
ISRCTN ISRCTN44725655
ClinicalTrials.gov identifier
Public title Comparison of Second-Line Hormonal Agents Medroxyprogesterone Acetate and Aminoglutethimide in Advanced Breast Cancer
Scientific title
Acronym N/A
Serial number at source BR3004
Study hypothesis Not provided at time of registration.
Ethics approval Not provided at time of registration.
Study design Randomised controlled trial
Countries of recruitment United Kingdom
Disease/condition/study domain Breast Cancer
Participants - inclusion criteria 1. Advanced breast cancer
2. Relapsed or failed following tamoxifen treatment
3. Postmenopausal
Participants - exclusion criteria Not provided at time of registration.
Anticipated start date 01/08/1991
Anticipated end date 01/08/1996
Status of trial Completed
Patient information material
Target number of participants Not provided at time of registration.
Interventions Patients are randomised to receive: 1. Group A: Medroxyprogesterone acetate 250 mg four times daily until disease progression or failure of treatment.
2. Group B: Aminoglutethimide 250 mg twice daily plus hydrocortisone 20 mg twice daily until disease progression or failure of treatment. There is a crossover option on disease progression or failure of treatment.
Primary outcome measure(s) Not provided at time of registration.
Secondary outcome measure(s) Not provided at time of registration.
Sources of funding Ciba-Geigy Pharmaceuticals, Farmitalia Carlo Erba
Trial website
Publications
Contact name Dr  -  -
  Address UKCCCR Register Co-ordinator
MRC Clinical Trials Unit
222 Euston Road
  City/town London
  Zip/Postcode NW1 2DA
  Country United Kingdom
  Tel +44 (0) 20 7670 4723
  Fax +44 (0) 20 7670 4818
  Email register@ctu.mrc.ac.uk
Sponsor Ciba-Geigy Pharmaceuticals (Switzerland)
  Address -
  City/town -
  Zip/Postcode -
  Country Switzerland
Date applied 19/08/2002
Last edited 10/03/2008
Date ISRCTN assigned 19/08/2002
Submit your trial protocol Top studies in medical research Submit to Trials journal
© ISRCTN


BioMed Central